Du är här

2016-02-03

Novo Nordisk A/S: Novo Nordisk increased operating profit by 43% in 2015 to DKK 49.4 billion

14% local currency operating profit growth adjusted for NNIT divestment

Sales increased by 22% in Danish kroner and by 8% in local currencies to 107.9
billion.

* Sales of modern and new-generation insulin increased by 22% (9% in local
currencies).
* Sales of Victoza®increased by 34% (18% in local currencies).
* Sales in North America increased by 32% (11% in local currencies).
* Sales in International Operations increased by 19% (15% in local
currencies).
* Sales in Region China increased by 22% (4% in local currencies).

Operating profit increased by 43% in Danish kroner and by 21% in local currencies to DKK 49.4 billion. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, the operating margin was 43.6% corresponding to an increase in operating profit in local currencies of 14%.

Net profit increased by 32% to DKK 34.9 billion. Diluted earnings per share
increased by 34% to DKK 13.52. Adjusted for the partial divestment of NNIT,
net profit and diluted earnings per share increased by 22% and 25%
respectively.

In 2015, Novo Nordisk achieved its four long-term financial targets
established in January 2013 and consequently, the Board of Directors has
approved three updated long-term financial targets to guide Novo Nordisk's
performance. The target for operating profit growth has now been set at 10%,
whereas no target for operating margin development has been established, as
the operating margin is expected to stay at the current level around 44%. The
targets for operating profit after tax to net operating assets and cash to
earnings remain unchanged at 125% and 90% respectively.

For 2016, sales growth is expected to be 5-9% measured in local currencies.
Growth in operating profit is also expected to be 5-9% measured in local
currencies, adjusted for the non-recurring impact of the partial divestment
of NNIT and the income related to the out-licensing of assets for
inflammatory disorders, both in 2015. Growth reported in DKK, for both items,
is expected to be around 1 percentage point lower than the local currency
levels.

At the Annual General Meeting on 18 March 2016, the Board of Directors will
propose a 28% increase in dividend to DKK 6.40 per share of DKK 0.20 and
intends to initiate a new 12-months share repurchase programme of up to DKK
14 billion.

Lars Rebien Sørensen, president and CEO: "We are very pleased with Novo
Nordisk's performance in 2015 and the achievement of our four long-term
financial targets. In 2016 we will continue to focus on the global launch of
Tresiba®and we are encouraged by the recent SWITCH 2 data, which further
demonstrate the ability of Tresiba®to reduce the risk of hypoglycaemia in
people with type 2 diabetes on basal insulin therapy."

Contacts for further information

-----------------------------------------------------------------
| Media: |
| Katrine Sperling +45 3079 6718 krsp@novonordisk.com |
| Ken Inchausti (US) +1 267 809 7552 kiau@novonordisk.com |
| Investors: |
| Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com |
| Daniel Bohsen +45 3079 6376 dabo@novonordisk.com |
| Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com |
| Kasper Veje +45 3075 8519 kpvj@novonordisk.com |
-----------------------------------------------------------------
Company announcement No 8 / 2015

Company announcement No 8 / 2016
http://hugin.info/2013/R/1983185/726759.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1983185

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.